Canada Markets open in 2 hrs 6 mins

Marvel Biosciences Corp. (MRVL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1050+0.0050 (+5.00%)
At close: 03:58PM EDT
Full screen
Previous Close0.1000
Open0.1050
Bid0.0700 x N/A
Ask0.1100 x N/A
Day's Range0.1050 - 0.1050
52 Week Range0.0850 - 0.3500
Volume500
Avg. Volume12,097
Market Cap3.422M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Marvel Announces Identification of a Novel Formulation of Its MB-204 Asset

    Calgary, Alberta--(Newsfile Corp. - July 21, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce that its rapid formulation screening program with Catalent, Inc., has identified a novel formulation of its lead asset MB-204.The formulation involves producing a solid amorphous dispersion of MB-204 using a simple, FDA approved excipient that has improved drug exposures by at least a factor of 20-fold. Improving oral bioavailability results in reduced amou

  • Newsfile

    Marvel Biosciences Closes First Tranche of Private Placement

    Calgary, Alberta--(Newsfile Corp. - July 18, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report that, further to its news release of June 21, 2022, it has closed the first tranche of its non-brokered private placement of 4,500,000 units of the Company (the "Units") at a price of $0.10 per Unit for gross proceeds of $450,000 (the "Offering"). Each ...

  • Newsfile

    Marvel Biosciences Announces Non-Brokered Private Placement

    Calgary, Alberta--(Newsfile Corp. - June 21, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce a proposed non-brokered private placement of units (the "Units") at a price of $0.10 per Unit for gross proceeds of up to $700,000 (the "Offering"). Each Unit will be comprised of one common share in the capital of the Company (a "Common Share") and ...